Last reviewed · How we verify

NCT05926401

Atrial Fibrillation Prior and Post Elective Cardioversion

Status unknown Last updated 30 November 2023
What this trial tests

trial testing ECG monitoring prior and after cardioversion in Atrial Fibrillation in 150 participants. Status unknown.

Timeline
1 September 2023
Primary endpoint
30 June 2024
31 December 2025

Quick facts

Lead sponsorSorlandet Hospital HF
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment150
Start date1 September 2023
Primary completion30 June 2024
Estimated completion31 December 2025
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

Sorlandet Hospital HF

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cardioversion from atrial fibrillation (AF) to sinus rhythm (SR) is performed primarily to improve patient symptoms. However, due to the intermittent nature of AF, patients may have converted to SR prior to elective cardioversion and the recurrence rate of AF after cardioversion can be high. The aims of this study are to assess the rate of spontaneously conversion to SR in patients with AF scheduled for elective cardioversion, as well as the rate of early recurrence of AF after elective cardioversion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Sorlandet Hospital HF trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05926401.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing